BamSEC and AlphaSense Join Forces
Learn More

Rein Therapeutics Inc. – Material Contracts

NASDAQ: RNTX    
Share price (3/27/26): $1.25    
Market cap (3/27/26): $35.0 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 27 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 27 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 40 pages Standby Equity Purchase Agreement
12/34/56
EX-10.1
from 8-K 41 pages Prepaid Advance Agreement
12/34/56
EX-10.4
from 8-K 17 pages Registration Rights Agreement
12/34/56
EX-10.3
from 8-K 9 pages Pre-Funded Warrant Subscription Agreement
12/34/56
EX-10.2
from 8-K 8 pages To the Holder of 2023 Warrant to Purchase Common Stock Re: Inducement Offer to Exchange 2023 Warrant to Purchase Common Stock Dear Holder
12/34/56
EX-10.1
from 8-K 9 pages Re: Inducement Offer to Exercise 2023 Warrant to Purchase Common Stock Dear Holder
12/34/56
EX-10.3
from 10-Q 3 pages Aileron Therapeutics, Inc. via Electronic Delivery March 23, 2024 Charles T. Gamer Re: Retention Agreement Dear Chuck
12/34/56
EX-10.2
from 10-Q 3 pages Lung Therapeutics, Inc
12/34/56
EX-10.1
from 10-Q 9 pages Employment Agreement
12/34/56
EX-10.42
from 10-K 23 pages Lung Therapeutics, Inc. 2013 Long-Term Incentive Plan
12/34/56
EX-10.11
from 10-K 13 pages Aileron Therapeutics, Inc. 2021 Stock Incentive Plan
12/34/56
EX-10.5
from 8-K 28 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. License Agreement by and Between Vivarta Therapeutics, L.L.C. and Lung Therapeutics, Inc
12/34/56
EX-10.4
from 8-K 32 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amended and Restated License Agreement by and Between Musc Foundation for Research Development and Lung Therapeutics, Inc
12/34/56
EX-10.3
from 8-K 34 pages Background
12/34/56
EX-10.2
from 8-K 28 pages Background
12/34/56
EX-10.1
from 8-K 50 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Exclusive License Agreement Between Taiho Pharmaceutical Co., Ltd. and Lung Therapeutics, Inc. a Texas Corporation Dated as of November 12, 2020
12/34/56
EX-10.5
from 8-K 2 pages Lung Therapeutics, Inc
12/34/56
EX-10.4
from 8-K 3 pages Lung Therapeutics, Inc
12/34/56